Related coverage linked through entity extraction aliases.
Apr 22, 2026
AI is reshaping pharma work by adding roles in drug discovery, commercial analytics and in-house AI teams rather than driving major job losses. Companies are also moving toward always-on intelligence as faster market shifts expose the limits of siloed, episodic insight models.
Apr 13, 2026
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab as AI drug discovery expands across research, trials and manufacturing. Companies including Recursion and Tempus are using large biological and clinical datasets to speed development and support precision medicine.
Apr 12, 2026
Generative AI processed complex medical datasets faster than traditional teams in a preterm birth study, while the healthcare market for the technology reached US$2.92 billion in 2024. The market is projected to grow to US$30.68 billion by 2033 as adoption expands in clinical workflows, imaging, drug discovery and precision medicine.
Mar 24, 2026
The AI-driven precision medicine market is projected to grow from $0.7 billion in 2025 to $9.7 billion by 2035 at a 26.8% CAGR. North America dominates with 62-67% market share, while machine learning accounts for 39% of the market. The market is moderately consolidated with the top five players controlling over 64% share.
Mar 20, 2026
The FDA announced major policy changes including requiring only one study for drug approvals instead of two, and offering performance bonuses to reviewers who complete work ahead of schedule while maintaining thoroughness.
Mar 19, 2026
Global pharmaceutical R&D deal values surged 49% to $86.7 billion in 2025 as companies concentrate investments in AI-powered drug discovery platforms, with average deal sizes reaching a record $1.16 billion despite fewer total partnerships.
Mar 17, 2026
Roche deployed 2,176 new NVIDIA Blackwell GPUs, bringing its total above 3,500 chips across on-premise and cloud infrastructure. The expansion follows Eli Lilly's 1,016-GPU supercomputer launch and Recursion's 504-GPU system unveiled in 2024.
Mar 10, 2026
GE HealthCare announced FDA 510(k) clearances for its View diagnostic viewer within the Genesis Radiology Workspace and three new Signa MRI systems, including helium-free technology and AI-powered workflow solutions.
Feb 24, 2026
Eli Lilly reported Q4 2025 EPS of $7.54 versus $6.67 expected and projected 2026 revenue of $80-83 billion. Mounjaro revenue surged 110% to $7.4B while Zepbound jumped 123% to $4.2B in Q4.
Feb 23, 2026
Merck and Mayo Clinic announced a research collaboration allowing Merck to use AI and advanced analytics with Mayo's clinical and genomic datasets for drug discovery, initially focusing on dermatology, neurology, and gastroenterology.
Feb 18, 2026
Artificial intelligence is transforming pharmaceutical industry employment by creating hybrid roles and in-house AI teams rather than causing widespread job losses, with drug discovery emerging as the primary area for AI talent demand.
Feb 17, 2026
Eli Lilly reported Q4 2025 EPS of $7.54 versus $6.67 expected and projected 2026 revenue of $80-83 billion. The company's GLP-1 drugs Mounjaro and Zepbound drove growth with revenues surging over 110%.
Feb 16, 2026
Eli Lilly committed $1 billion to build an AI-powered supercomputer with Nvidia for drug discovery, launching its TuneLab platform in September and establishing a co-innovation lab by January.
Feb 14, 2026
Life sciences companies are integrating AI into clinical trial operations to reduce administrative burden and improve efficiency, while the biotechnology sector experiences a structural transformation driven by AI industrialization and institutional capital.
Feb 14, 2026
Pharmaceutical companies are deploying AI and machine learning across clinical trial execution, regulatory submissions, and drug discovery to address rising costs and lengthy timelines in drug development.
Feb 13, 2026
Artificial intelligence is accelerating drug discovery from molecule screening to clinical trials, but legal uncertainty over patent ownership and profit distribution threatens to slow progress as the technology reshapes pharmaceutical development.
Feb 13, 2026
Eli Lilly has accumulated $1.5 billion in pre-launch inventory of its experimental oral weight-loss drug orforglipron ahead of an expected FDA decision in April, up from $550 million last year.
